Chantalle Butler's promotion is hailed as a positive step, thanks to her significant role in the company's growth strategy. Her leadership style and commitment to growth are expected to continue propelling Molson Coors' success in Canada.
Laboy believes Molson Coors might face a tough growth path post-2024 due to lack of innovation and struggles to upscale Blue Moon brand. High-single-digit EPS growth target may be hard to reach, says Laboy.
Deutsche Bank analysts express that current Molson Coors stock valuation has already factored in growth maintenance risks. They also highlight improvements in company operations due to portfolio optimization, marketing focus, and modernization efforts. Yet, they flag caution given probable Q4 softness from planned maintenance and the effort to end the year with a sound inventory.
MKM's Roth analyst Bill Kirk has an optimistic view on Molson Coors, noting its promising prospects to overturn five years of U.S. volume declines via a more efficient cost structure. The shift of market share from Bud Light to Miller Lite and Coors Light due to a conservative-led boycott is expected to be quite profitable and sticky.
Analyst Bill Kirk perceives a profitable market shift from Bud Light to Miller Lite and Coors Light. He maintains a buy rating on the stock, hinting at an appealing prospect of reversing US volume declines.
Despite recent stock dip, investors remain optimistic due to strong returns over three years. Note, however, the need to consider investment risks and dividend contributions to total shareholder returns.
Weight-loss drug stocks are the big winners in the market as investors got clear evidence that these drugs could be a game-changer for the pharmaceutical industry. While other companies—including those outside of healthcare—could feel a more negative impact. Morgan Stanley anticipated annual global sales for weight-loss drugs could reach $77 billion by 2030, higher than its previous $54 billion forecast.$ノボ・ノルディスク(NVO.US)$and$イーライリリー(LLY.US)$will spli...
モルソン・クアーズ・ビバレッジに関するコメント
4 Dividend Stocks to Buy Now & Hold Forever!!
$EOGリソーシズ(EOG.US)$$FS KKRキャピタル(FSK.US)$$モルソン・クアーズ・ビバレッジ(TAP.US)$$CFインダストリーズ・ホールディングス(CF.US)$$モザイク(MOS.US)$$YIELDMAX NVDA OPTION INCOME STRATEGY ETF(NVDY.US)$
$ウォーターズ(WAT.US)$$モルソン・クアーズ・ビバレッジ(TAP.US)$$アンハイザー・ブッシュ・インベブ(BUD.US)$$コカ・コーラ(KO.US)$$ザイレム(XYL.US)$$ThaiBev(Y92.SG)$$レナー(LEN.US)$$D.R.ホートン(DHI.US)$$ペプシコ(PEP.US)$$スリーエム(MMM.US)$$アプライド マテリアルズ(AMAT.US)$$ネットフリックス(NFLX.US)$$アドバンスト・マイクロ・デバイス(AMD)(AMD.US)$$ルルレモン・アスレティカ(LULU.US)$
コラムWeight-Loss Drug Craze: The Potential Winners and Losers
Morgan Stanley anticipated annual global sales for weight-loss drugs could reach $77 billion by 2030, higher than its previous $54 billion forecast. $ノボ・ノルディスク(NVO.US)$ and $イーライリリー(LLY.US)$ will spli...
Daily alerts recap 🔥
まだコメントはありません